Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Nucleic Acid Binding	NCIT_C40523	[Nucleic Acid Binding involves temporary non-covalent interaction of a protein or low molecular weight ligand through intermolecular physical forces of attraction with DNA or RNA, in either a sequence dependent or independent fashion.]
FAMS - My Work is Fulfilling	NCIT_C112572	[Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: My work (include work at home) is fulfilling.]
Nucleoside Receptor Binding	NCIT_C40524	[A process that involves the non-covalent binding of nucleosides to nucleoside receptor proteins. This interaction plays a role in the initiation of signal transduction.]
FAMS - I Have Accepted My Illness	NCIT_C112573	[Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I have accepted my illness.]
Monoclonal Antibody 3F8/Sargramostim	NCIT_C15590
Monoclonal Antibody 3F8	NCIT_C2370	[A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)]
Prevention of Ovarian Cancer	NCIT_C15591
Incomplete Freund's Adjuvant/MART-1	NCIT_C15592
gp100 Antigen/Interleukin-2	NCIT_C15593
Interleukin-2/Monoclonal Antibody HuG1-M195	NCIT_C15594
Lintuzumab	NCIT_C1716	[A humanized recombinant monoclonal antibody directed against CD33, a cell surface antigen found on myeloid leukemia blasts and early hematopoietic progenitor cells. Lintuzumab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing CD33, resulting in a decrease in tumor burden. The humanized version of this monoclonal antibody exhibits less immunogenicity and improved binding affinity compared to its murine counterpart.]
Transitional Care Planning	NCIT_C15595
Interleukin-2/Vinblastine	NCIT_C15596
Vinblastine	NCIT_C930	[A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)]
Incomplete Freund's Adjuvant/Interleukin-12/MART-1 Antigen	NCIT_C15597
Incomplete Freund's Adjuvant	NCIT_C1573	[A water-in-oil emulsion that stimulates the T-cell immune response to antigens and may be used in various types of cancer vaccines. (NCI04)]
Recombinant Interleukin-12	NCIT_C1380	[A recombinant form of the endogenous heterodimeric cytokine interleukin-12 with potential antineoplastic activity. Recombinant interleukin-12 binds to and activates its cell-surface receptor, stimulating the production of interferon-gamma (IFN) which, in turn, induces IFN-gamma-inducible protein-10 (IP-10) and so inhibits tumor angiogenesis. (NCI04)]
MART-1 Antigen	NCIT_C28724	[A tumor-associated melanocytic differentiation antigen. Vaccination with MART-1 antigen may stimulate a host cytotoxic T-cell response against tumor cells expressing the melanocytic differentiation antigen, resulting in tumor cell lysis. (NCI04)]
Bispecific Antibody 520C9XH22/Filgrastim	NCIT_C15598
Filgrastim	NCIT_C1474	[A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.]